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Abstract Small cell carcinoma of the ovary, hypercal-
cemic type, (SCCOHT) is the most common undifferenti-
ated ovarian cancer in women aged under 40 years.
SCCOHT is a monogenic disease, characterized by germ-
line and somatic SMARCA4 mutations. Recent studies have
stressed its morphological and clinical similarity to
malignant rhabdoid tumours, which are usually caused by
mutations in the related gene, SMARCB1. While familial
tumours are rare, the incidence of germline mutations is
relatively high, with up to 43% of SCCOHTs and 35% of
rhabdoid tumours caused by germline mutations in
SMARCA4 and SMARCB1, respectively. We report two
new familial cases of SCCOHT. Affected members in both
families and the associated tumours were found to carry
SMARCA4 germline and somatic mutations, respectively,
leading to loss of SMARCA4 protein expression in the
tumours. Despite the rarity of familial SCCOHT, the high
incidence of germline mutations is important to note, as
without a family history of the disease, the hereditary
nature of SCCOHT may be missed, especially if the
mutation was inherited from the father or acquired de novo.
The similarity between SCCOHT and rhabdoid tumours
should be recognized, as infant carriers of SMARCA4
mutations may be at risk for these tumours in addition to
SCCOHT.
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Introduction
Small cell carcinoma of the ovary, hypercalcemic type
(SCCOHT) is the most common undifferentiated form of
ovarian cancer in women below age 40. It is an aggressive
cancer with 5-year survival rates of 53.8% in stage I dis-
ease [1]. SCCOHT is a monogenic and at times hereditary
disease, characterized by germline and somatic mutations
in the chromatin remodelling gene, SMARCA4, a member
of the SWI/SNF complex [1]. Further analyses have
revealed that these tumours are very similar to rhabdoid
tumours (RTs) on clinical, morphological, and genetic
levels. As such, we have proposed that SCCOHT should be
regarded as an RT of the ovary [2]. RTs are pediatric soft
tissue tumours that usually arise in the kidney but can arise
elsewhere, and along with the intracranial variant, called
atypical teratoid/rhabdoid tumours (ATRTs), they are
usually characterized by mutations in SMARCB1, another
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gene in the SWI/SNF complex. In rare instances, however,
RTs are caused by mutations in SMARCA4 [3]. These
mutations almost always lead to loss of their encoded
protein (SMARCA4 or SMARCB1) by immunohisto-
chemistry, making this an important diagnostic marker for
these tumours [1].
In rare instances, RTs and SCCOHTs have been found
to arise in familial settings due to germline mutations in
either SMARCA4 or SMARCB1 [1]. Up to 35% of RTs are
caused by germline SMARCB1 mutations [4], and up to
43% of SCCOHTs by germline SMARCA4 mutations [1];
this has implications for management of the diseases in the
affected families. Germline SMARCB1 or SMARCA4
mutations define rhabdoid tumour predisposition syndrome
type 1 (RTPS1; OMIM #609322) or type 2 (RTPS2, OMIM
#613325), respectively. Although the ovarian type of RT
(SCCOHT) is almost always caused by mutations in
SMARCA4, and extra-ovarian RT by mutations in
SMARCB1, it is possible for multiple tumour types within
the rhabdoid tumour spectrum to be caused by the same
mutation [3–5].
Here we describe two previously unpublished families,
both consisting of two females with SCCOHT. The affec-
ted women were diagnosed between the ages of 23 and 36,
and three of the four eventually succumbed to their disease.
We discuss the implications of familial occurrence of
SCCOHT and propose necessary steps for diagnosis and
management of the disease in a genetic context.
Materials and methods
Samples
DNA was extracted from patients’ blood and FFPE tumour
tissue as previously described. RNA was extracted from
patients’ blood as previously described [6].
Sanger sequencing and immunohistochemistry were
performed as previously described [5].
Results
Family 1
Family 1 consists of a proband who was diagnosed with
SCCOHT at age 23 years (Fig. 1a, patient III:1) and her
paternal half-sister (Fig. 1a, patient III:3), who was diag-
nosed with SCCOHT at age 30. Patient III:1 was diagnosed
with FIGO stage IC SCCOHT of the right ovary. Bilateral
salpingo-oophorectomy and omentectomy, followed by
cisplatin and etoposide with adjuvant pelvic radiation
achieved a complete response. However, she relapsed in a
periaortic lymph node eighteen months after diagnosis and
received further cisplatin and etoposide as well as adjuvant
radiotherapy to the periaortic nodal recurrence. She
underwent subsequent exploratory laparotomy and resec-
tion of the right periaortic mass. She is currently recovering
from surgery.
Patient III:3, the half-sister of patient III:1, was diag-
nosed with FIGO stage IIIB SCCOHT of the left ovary.
She underwent a left salpingo-oophorectomy, right
oophorectomy, omentectomy, and peritoneal biopsies. Her
omentum and peritoneal biopsies showed involvement by
tumour. She received cisplatin plus etoposide for one cycle
with no response. Six weeks after diagnosis she received
palliative radiation for three weeks and died 2 weeks later,
three months after the original diagnosis.
The patients’ family history is remarkable in that their
father (Fig. 1a, patient II:2), a smoker, had died from
metastatic lung carcinoma at age 53 with underlying
chronic obstructive pulmonary disease. Histologically, his
lung tumor was a mucinous adenocarcinoma without any
rhabdoid features. All three patients were found to carry a
germline splice mutation in the SMARCA4: c.2859?1G[C,
which led to an in-frame deletion of exon 19 (Fig. 1b).
Both women showed loss of heterozygosity (LOH) of the
mutation in their SCCOHT (Fig. 1b). The SMARCA4
protein was immunohistochemically lost in both SCCOHTs
(Fig. 1c) and the lung carcinoma (Fig. 1d). The second
half-sister of the proband (Fig. 1a, patient III:4) as well as
the daughter of patient III:2 (Fig. 1a, patient IV:1) were
both found to carry the familial germline mutation. Patient
III:4 underwent a prophylactic oophorectomy, while
patient IV:1 is being followed with biannual pelvic ultra-
sonography. It should be noted that this screening has not
been proven to be effective and should not replace
oophorectomy as a management strategy, particularly for
those women who have completed child-bearing.
Family 2
Family 2 consists of a proband who was diagnosed with
SCCOHT at age 23 (Fig. 2, patient III:2) and her mother
(Fig. 2, patient II:3), who had been diagnosed with an ovarian
‘‘rhabdoid tumour’’, consistent with a diagnosis of SCCOHT
19 years earlier, at age 36 (see below). Patient III:2 (Fig. 2)
was diagnosed with FIGO stage IIIB SCCOHT of the right
ovary. She underwent a right salpingo-oophorectomy, an
omentectomy, and resection of right periaortic and pelvic
lymph nodes. There was tumour involvement of the abdom-
inal peritoneum and metastases to her pelvic and periaortic
lymph nodes. She received 6 cycles of chemotherapy, con-
sisting of cisplatin and etoposide. She then received radio-
therapy and single agent taxol for 4 cycles but rapidly
progressed and died 14 months post diagnosis.
L. Witkowski et al.
123
Patient II:3 was the mother of Patient III:2. At age 36,
she was diagnosed with a ‘‘poorly differentiated adeno-
carcinoma with extensive rhabdoid features’’ of her right
ovary. We now know that this description is compatible
with a diagnosis of SCCOHT, but when she was diagnosed,
SCCOHT was a relatively newly described entity (first
described in 1979 [7]). The patient underwent a total
abdominal hysterectomy, bilateral salpingo-oophorectomy,
omentectomy, and tumour debulking. Due to her unsta-
ble condition post-operatively no chemotherapy was given.
The patient died three weeks after her original diagnosis.
Aside from the two affected women, the family history
was unremarkable (Fig. 2a). The SMARCA4 gene was
sequenced in germline and tumour DNA of both patients
and a germline nonsense mutation was found: c.175C[T;
p.Asn59* (Fig. 2b). The tumour of patient III:2 harboured
a second somatic mutation: c.2375T[C; p.Leu792Pro.
The tumours of both patients displayed loss of the
SMARCA4 protein by immunohistochemistry (Fig. 2C).
The sister of the proband did not carry the familial germ-
line mutation.
Discussion
Here we report two new familial occurrences of SCCOHT.
Previously, only four familial cases of SCCOHT were
sequenced, and all affected patients were found to carry
SMARCA4 mutations with second somatic mutations in
their tumours (Table 1) [1]. While the incidence of
SCCOHT occurring in families is low, the incidence of
germline mutations in SCCOHT patients is relatively high
(43%) [1]. This is likely due to the fact that this tumour
characteristically occurs in young females (and at a
Fig. 1 Family 1. a Pedigree of family 1. b Mutations found by
Sanger sequencing in affected patients. Top: Germline mutation found
in both patients; middle: representative chromatogram from patient
III:1 showing somatic LOH found in tumours of both patients;
bottom: cDNA sequencing across mutation, showing that splice
mutation leads to skipping of exon 19. Loss of expression was seen in
both SCCOHT tumors and representative SMARCA4 immunohisto-
chemistry is shown in two tumors—c in the SCCOHT from patient
III:3, with complete loss of SMARCA4 staining and positive internal
controls and d: in the lung tumor from patient II:4. In d immunohis-
tochemistry for SMARCA4 shows loss of nuclear SMARCA4
staining in pleomorphic tumor cells, but retained staining in small
round lymphocytic nuclei (internal positive control). Original mag-
nification 6009. TAH/BSO, total abdominal hysterectomy/bilateral
salpingo-oophorectomy
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younger age in those with germline mutations than those
with only somatic mutations [1]). Most carriers are diag-
nosed prior to having children and either die of their dis-
ease, or survive infertile due to therapy. Furthermore, half
of patients with germline mutations have been found to
inherit the mutation from their father [1]. Only one case of
RT of the ovary has been reported to be due to a de novo
germline mutation, and the daughter of the patient devel-
oped an ATRT [5].
The unknown penetrance of these mutations remains a
challenge when counselling patients and their families.
Only one female SMARCA4 carrier has been reported to
remain healthy past her sixth decade; this was the grand-
mother of an ATRT patient [3]. Further testing of affected
and unaffected family members will hopefully elucidate
the true penetrance and allow carriers to be more informed
when making potentially life-altering decisions, such as
prophylactic oophorectomies [8].
Due to the high incidence of germline mutations in
SCCOHT, it is recommended that all patients with the
disease undergo genetic testing. Although it has not been
shown to alter the treatment or outcome of patients, it can
benefit relatives who may carry the mutation. Female
carriers of truncating mutations are at risk for SCCOHT,
and infant carriers of both genders may be at risk for RTs.
SMARCA4-mutated RTs have not been seen in patients
older than 46 months [3], so the development of these
tumours in older carriers is unlikely. However, the oldest
woman to date diagnosed definitively with SCCOHT
(showing loss of SMARCA4 staining in her tumour) was
56 years old at diagnosis. As SMARCA4 mutations overlap
between SCCOHT and RTs, it is still unknown why
patients develop one tumour over the other. While the lung
tumour of the father in Family 1 showed loss of expression
of SMARCA4, it is unclear whether the cancer was related
to the SMARCA4 germline mutation; the patient was a
smoker and many lung tumours display loss of SMARCA4
expression [9].
The types of SMARCA4 mutations seen in SCCOHT
vary, yet all but two have led to loss of expression of the
protein, with the remaining two being a missense and an in-
frame deletion [1]. Germline mutations in SMARCA4,
SMARCB1, and other SWI/SNF components also cause
Coffin-Siris syndrome (CSS) [10, 11], a developmental
disorder primarily characterized by developmental delay
and intellectual and physical disabilities. Interestingly,
Fig. 2 Family 2. a Pedigree of family 2. b Mutations found by
Sanger sequencing in affected patients. Top germline mutation found
in both patients; middle LOH seen in tumour from patient II:3; bottom
somatic LOH found in tumours of both patients. c Representative
SMARCA4 immunohistochemistry in tumour of patient III:2. Loss of
expression was seen in both patients. Pr Ca, Prostate cancer
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germline SMARCA4 and SMARCB1 mutations causing
CSS have mostly been missense and de novo, whereas
those causing RTs or SCCOHT have mostly been trun-
cating and inherited, with only one reported RT caused by
a de novo SMARCA4 mutation [5]. Unlike in SCCOHT and
RTs, no overlap of mutations has been reported between
CSS and either SCCOHT or RT. Furthermore, no patients
with SMARCA4-deficient cancers have been reported to
show a CSS phenotype, and no CSS patients have been
found to develop RTs. However, one patient with a
SMARCB1 mutation and CSS has been reported to develop
schwannomatosis, another type of tumour caused by
germline SMARCB1 mutations [12]. The mutations leading
to schwannomatosis are most often missense variants, but
may be loss of function as well. Interestingly, in some
patients with loss of function mutations, the SMARCB1
mRNA has been found to escape degradation by reinitiat-
ing translation at the AUG codon encoding methionine at
position 27 of the SMARCB1 protein [13]. While it is still
not entirely clear why some mutations in the SWI/SNF
complex predispose to cancer, while others lead to intel-
lectual disability, but it has been postulated that the
mutations in any of the SWI/SNF complex members that
lead to developmental disorders exert either dominant-
negative or gain-of-function effects, while those leading to
SCCOHT are loss-of-function mutations [10]. Similarly,
both loss of function and missense mutations in SMARCB1
can lead to schwannomatosis [14], and it still remains
unclear why some carriers develop schwannomas, while
other develop RTs.
Although the familial incidence of SCCOHT is low, it is
important to note the high fraction caused by germline
SMARCA4 mutations and to recognize that even without a
family history, it may be hereditary, for example if the
patient has inherited a germline mutation from her father or
acquired one de novo. Furthermore, the similarity between
SCCOHT and RTs is striking and, in addition to SCCOHT,
infant SMARCA4 mutation carriers may be at risk for these
tumours.
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